- Home
- MDCX vs QNCX Comparison
MDCX vs QNCX Comparison
Compare MDCX & QNCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MDCX
- QNCX
- Stock Information
- Founded
- MDCX 2008
- QNCX 2012
- Country
- MDCX Canada
- QNCX United States
- Employees
- MDCX N/A
- QNCX N/A
- Industry
- MDCX
- QNCX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MDCX
- QNCX Health Care
- Exchange
- MDCX Nasdaq
- QNCX Nasdaq
- Market Cap
- MDCX 48.4M
- QNCX 43.2M
- IPO Year
- MDCX N/A
- QNCX 2019
- Fundamental
- Price
- MDCX $2.50
- QNCX $1.04
- Analyst Decision
- MDCX Strong Buy
- QNCX Strong Buy
- Analyst Count
- MDCX 2
- QNCX 5
- Target Price
- MDCX $23.50
- QNCX $8.00
- AVG Volume (30 Days)
- MDCX 383.9K
- QNCX 611.7K
- Earning Date
- MDCX 05-12-2025
- QNCX 05-13-2025
- Dividend Yield
- MDCX N/A
- QNCX N/A
- EPS Growth
- MDCX N/A
- QNCX N/A
- EPS
- MDCX N/A
- QNCX N/A
- Revenue
- MDCX N/A
- QNCX N/A
- Revenue This Year
- MDCX N/A
- QNCX N/A
- Revenue Next Year
- MDCX N/A
- QNCX N/A
- P/E Ratio
- MDCX N/A
- QNCX N/A
- Revenue Growth
- MDCX N/A
- QNCX N/A
- 52 Week Low
- MDCX $1.80
- QNCX $0.51
- 52 Week High
- MDCX $8.94
- QNCX $2.45
- Technical
- Relative Strength Index (RSI)
- MDCX N/A
- QNCX 50.67
- Support Level
- MDCX N/A
- QNCX $1.01
- Resistance Level
- MDCX N/A
- QNCX $1.06
- Average True Range (ATR)
- MDCX 0.00
- QNCX 0.11
- MACD
- MDCX 0.00
- QNCX 0.02
- Stochastic Oscillator
- MDCX 0.00
- QNCX 79.40
About MDCX Medicus Pharma Ltd. Common Stock
Medicus Pharma Ltd is a clinical-stage holding company focused on investing in and accelerating novel life sciences and bio-technology companies through FDA-approved clinical trials. The Company focuses on meeting the unmet need to improve patient safety and efficacy.
About QNCX Quince Therapeutics Inc.
Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics. Company pipeline includes Ataxia-Telangiectasia(EryDex), Duchenne Muscular Dystrophy, New Indications and Program Expansion Potential.